Medical devices, healthcare technology and the business of care
PMA approval · P950037

DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS

Biotronik, Inc. · Decision date Oct 11, 1996

MEDTECHLEDGER EXPLANATIONP950037

What did the FDA approve?

FDA approved PMA P950037 on October 11, 1996, for the DROMOS DR/DR-A and DROMOS SR/SR-B cardiac pacing systems from Biotronik, Inc. The approval statement describes rate adaptive pacing with these pulse generators as indicated for patients exhibiting chronotropic incompetence who would benefit from increased pacing rates concurrent with physical activity.

The source statement reports an intended patient population and functional purpose, not an independent demonstration of safety or clinical effectiveness. The record does not identify a supplement type or reason, so no relationship to a prior PMA scope change can be established from the supplied fields.

FDA approval order statement

RATE ADAPTIVE PACING WITH THE DROMOS DR AND DROMOS SR PULSE GENERATORS IS INDICATED FOR PATIENTS EXHIBITING CHRONOTROPIC INCOMPETENCE AND WHO WOULD BENEFIT FROM INCREASED PACING RATES CONCURRENT WITH PHYSICAL ACTIVITY
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Oct 11, 1996

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P950037
Regulatory pathway
Premarket approval application
Product code
DXY
Decision code
APPR
Decision date
Oct 11, 1996
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: implantable pacemaker Pulse-generator.

Product code
DXY
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P950037 received

    Application receipt date recorded by FDA.

  2. P950037 · FDA decision

    APPR

  3. P950037/S291 · Related supplement

    PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg

  4. P950037/S279 · Related supplement

    Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-

  5. P950037/S296 · Related supplement

    Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-

  6. P950037/S298 · Related supplement

    Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos

  7. P950037/S299 · Related supplement

    Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8

  8. P950037/S300 · Related supplement

    Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,

Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P950037

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records